ReviewMolecular biology reports2025
A rare case of LORICRIN gene c.684dup mutation associated with Vohwinkel syndrome in a Turkish patient, in silico analysis and literature review.
Review in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVohwinkel Syndrome (VS) is a rare autosomal dominant skin disorder with two main mutation types: the classic form caused by GJB2 gene mutations and loricrin keratoderma (LK) linked to LOR gene mutations. LK typically lacks hearing loss and often presents at birth as collodion baby syndrome.
methodsA 7-year-old male proband presenting with congenital thickening of the palms and soles was admitted to Başakşehir Çam and Sakura City Hospital. Whole-exome sequencing was performed from a whole blood sample using the MGI-400 platform, and common or benign mutations were excluded. Segregation analysis confirmed a pathogenic LOR mutation. Wild-type and mutant loricrin structures were modeled using I-TASSER and refined with ModRefiner. Protein interactions were analyzed via STRING, and docking with TGase 3 was performed using HDOCK. Structural visualization was completed using UCSF Chimera.
resultsA specific LOR mutation [NM_000427.3 c.684dup p.(Ser229ValfsTer107)] was identified, associated with palmoplantar keratoderma, ichthyosis-like plaques on the elbows and knees, anhidrosis, and absence of dental abnormalities, consistent with typical loricrin keratoderma (LK) cases. In silico analysis revealed that wild-type loricrin binds transglutaminase 3 (Tgase 3) with a lower score, and serine interactions present in normal loricrin were absent in the mutant form. Frameshift mutations also reduced glycine motifs critical for epidermal protein organization and skin flexibility.
conclusionGenetic testing is essential for accurate diagnosis and differentiation of LK from other VS types. This case highlights the importance of genetic screening for early diagnosis and improved management, ultimately enhancing patient care in rare populations.
Indexed as
Identifiers
41307748What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.